AU2011322482B2 - Treatment for Dupuytren's disease - Google Patents

Treatment for Dupuytren's disease Download PDF

Info

Publication number
AU2011322482B2
AU2011322482B2 AU2011322482A AU2011322482A AU2011322482B2 AU 2011322482 B2 AU2011322482 B2 AU 2011322482B2 AU 2011322482 A AU2011322482 A AU 2011322482A AU 2011322482 A AU2011322482 A AU 2011322482A AU 2011322482 B2 AU2011322482 B2 AU 2011322482B2
Authority
AU
Australia
Prior art keywords
disease
antagonist
tnf
dupuytren
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011322482A
Other languages
English (en)
Other versions
AU2011322482A1 (en
Inventor
Kim Suzanne Midwood
Jagdeep Nanchahal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1018325.9A external-priority patent/GB201018325D0/en
Priority claimed from GBGB1018362.2A external-priority patent/GB201018362D0/en
Priority claimed from GBGB1113718.9A external-priority patent/GB201113718D0/en
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU2011322482A1 publication Critical patent/AU2011322482A1/en
Assigned to OXFORD UNIVERSITY INNOVATION LIMITED reassignment OXFORD UNIVERSITY INNOVATION LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: ISIS INNOVATION LTD
Application granted granted Critical
Publication of AU2011322482B2 publication Critical patent/AU2011322482B2/en
Priority to AU2017204267A priority Critical patent/AU2017204267B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2011322482A 2010-10-30 2011-10-31 Treatment for Dupuytren's disease Active AU2011322482B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017204267A AU2017204267B2 (en) 2010-10-30 2017-06-23 Treatment for dupuytren's disease

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1018325.9A GB201018325D0 (en) 2010-10-30 2010-10-30 Treatment for dupuytren's disease
GB1018325.9 2010-10-30
GBGB1018362.2A GB201018362D0 (en) 2010-11-01 2010-11-01 Treatment of dupuytren's disease
GB1018362.2 2010-11-01
GB1113718.9 2011-08-10
GBGB1113718.9A GB201113718D0 (en) 2011-08-10 2011-08-10 Treatment of Dupuytren's Disease
PCT/EP2011/069147 WO2012056044A1 (en) 2010-10-30 2011-10-31 Treatment for dupuytren's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204267A Division AU2017204267B2 (en) 2010-10-30 2017-06-23 Treatment for dupuytren's disease

Publications (2)

Publication Number Publication Date
AU2011322482A1 AU2011322482A1 (en) 2013-05-23
AU2011322482B2 true AU2011322482B2 (en) 2017-03-23

Family

ID=44913268

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011322482A Active AU2011322482B2 (en) 2010-10-30 2011-10-31 Treatment for Dupuytren's disease
AU2017204267A Active AU2017204267B2 (en) 2010-10-30 2017-06-23 Treatment for dupuytren's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017204267A Active AU2017204267B2 (en) 2010-10-30 2017-06-23 Treatment for dupuytren's disease

Country Status (9)

Country Link
US (3) US9138458B2 (enExample)
EP (1) EP2632446B1 (enExample)
JP (2) JP6004494B2 (enExample)
AU (2) AU2011322482B2 (enExample)
CA (1) CA2847197C (enExample)
DK (1) DK2632446T3 (enExample)
ES (1) ES2715204T3 (enExample)
RU (1) RU2013123796A (enExample)
WO (1) WO2012056044A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632446B1 (en) 2010-10-30 2018-12-12 Oxford University Innovation Limited Treatment for dupuytren's disease
EP2844276B1 (en) 2012-05-01 2019-10-02 Proteolease Ltd. Methods for extracting a tooth
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
US20160158325A1 (en) * 2013-07-11 2016-06-09 180 Therapeutics Lp Method of treating fibroproliferative disorders including dupuytren's disease with one or more specific human matrix metalloproteinase and a tnf antagonist
WO2016140921A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist
AU2017248273B2 (en) * 2016-04-08 2024-03-14 180 Therapeutics Lp Method of treating early stage Dupuytren's disease
US20190225682A1 (en) * 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
WO2018045213A1 (en) * 2016-09-02 2018-03-08 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
US11564963B2 (en) 2017-11-22 2023-01-31 Progeneron, Llc Topical compositions, process of large-scale manufacture, and method of use
EP3980022B1 (en) * 2019-06-07 2025-01-15 Dale Biotech, LLC Treatment of dupuytren's disease, osteoarthritis, or adhesive capsulitis with rhamnolipids.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056079A1 (en) * 1994-07-19 2001-12-27 Hans-Arne Hansson Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site
WO2005074913A2 (en) * 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1083337C (zh) 1996-03-26 2002-04-24 精工爱普生株式会社 打印装置及其控制方法
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
GB0105330D0 (en) 2001-03-02 2001-04-18 Renovo Ltd Genetic testing
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
JP2004532230A (ja) * 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
US7553488B2 (en) 2002-07-05 2009-06-30 UNIVERSITé LAVAL Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions
GB0306165D0 (en) 2003-03-18 2003-04-23 Delta G Ltd Medical treatment
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US20060204488A1 (en) * 2005-01-21 2006-09-14 Badalamente Marie A Methods for treating adhesive capsulitis
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
JP5649589B2 (ja) 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
AU2010221213B2 (en) 2009-03-06 2014-10-23 Kenneth William Gregg Composition for controlling fish
EP2632446B1 (en) * 2010-10-30 2018-12-12 Oxford University Innovation Limited Treatment for dupuytren's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056079A1 (en) * 1994-07-19 2001-12-27 Hans-Arne Hansson Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site
WO2005074913A2 (en) * 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BISSON, M. A. et al Journal of Hand Surgery, Vol. 28, No. 4, page 351-356. 2003. *
HURST, L.C. et al NEJM, Vol. 361, No. 18, page 968-979. 2009. *
KHANNA, D. et al Rheumatology, Vol. 49, page 1184-1188. 1 June 2010. *
PILCHER, B. et al Anatomical Record, Vol. 229, No. 4, page 70A. 1991. *

Also Published As

Publication number Publication date
JP2017014266A (ja) 2017-01-19
ES2715204T3 (es) 2019-06-03
JP2013540803A (ja) 2013-11-07
US20190322733A1 (en) 2019-10-24
EP2632446B1 (en) 2018-12-12
AU2017204267A1 (en) 2017-07-13
AU2017204267B2 (en) 2019-05-23
US9138458B2 (en) 2015-09-22
CA2847197C (en) 2020-11-03
US20130287760A1 (en) 2013-10-31
US20160280775A1 (en) 2016-09-29
US10273296B2 (en) 2019-04-30
RU2013123796A (ru) 2014-12-10
CA2847197A1 (en) 2012-05-03
DK2632446T3 (en) 2019-04-01
EP2632446A1 (en) 2013-09-04
WO2012056044A1 (en) 2012-05-03
US10669334B2 (en) 2020-06-02
AU2011322482A1 (en) 2013-05-23
JP6004494B2 (ja) 2016-10-12

Similar Documents

Publication Publication Date Title
US10669334B2 (en) Treatment for Dupuytren's disease
JP7558900B2 (ja) 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
KR101397912B1 (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
US10858449B1 (en) Methods and compositions for treating osteoarthritis
US10961321B1 (en) Methods and compositions for treating pain associated with inflammation
JP2008530003A (ja) 創傷治癒を向上させるための、および線維症予防のためのミオスタチン（ｇｄｆ−８）アンタゴニストの使用
Huang et al. Pharmacological treatment for keloids
US10995151B1 (en) Methods and compositions for treating disease-related cachexia
Yaden et al. Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice
US11518801B1 (en) Methods and compositions for treating diabetes and diabetic complications
US20240000930A1 (en) Methods and compositions for treating kidney diseases
JP2011506371A (ja) 抗Ｆａｓリガンド抗体を含有する天疱瘡の治療薬
US20240101658A1 (en) Osteopontin monoclonal antibodies for cancer and osteoporosis immunotherapy
WO2024102157A1 (en) Methods and compositions for treating diabetes and diabetic complications
WO2013064585A1 (en) Treatment of musculoskeletal fibroproliferative disorders
KR102206017B1 (ko) Parp1 저해제를 포함하는 피부 섬유화 질환 치료용 약학적 조성물
RU2672377C1 (ru) Способ лечения ран
Nowak et al. The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy
Nanchahal et al. Treatment for dupuytren's disease
WO2022197703A1 (en) Wound healing enhancement with anti-ceramide antibodies
US11946094B2 (en) Combination therapies and methods of use thereof
US12221463B2 (en) Method of promoting wound healing by inhibiting CCR3
CN121003696A (zh) 一种靶向b细胞和软骨细胞衰老的骨关节炎治疗药物
Saraceno et al. Recent patents and new strategies in the treatment of psoriasis
Thiolat et al. SAT0038 Non viral gene therapy by IL-35 gene electrotransfer. Application to the treatment of collagen arthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)